Drug Profile

JL 19001

Alternative Names: JL-19001

Latest Information Update: 25 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator JECHO Biopharmaceuticals
Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
Mechanism of Action Interleukin 15 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

19 Mar 2026 JECHO Biopharmaceuticals plans a phase-I/II trial for Bladder cancer (Monotherapy, Combination therapy) in March 2026 (Intravesicular), (NCT07483970)
31 Mar 2025 Preclinical trials in Solid tumours in China (Parenteral) (JECHO Biopharmaceuticals pipeline; March 2025)
30 May 2024 Jecho Laboratories files for patent protection for "Interleukin-15 fusion protein and methods of use"

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com